07:22 AM EDT, 05/18/2026 (MT Newswires) -- Merck &Co.(MRK) said Monday its investigational sacituzumab tirumotecan therapy met primary endpoints of overall survival and progression-free survival in a phase 3 trial for advanced or recurrent endometrial cancer.

The medication improved survival metrics and achieved its secondary objective response rate goal compared to standard chemotherapy in patients previously treated with other therapies, the company said.

The safety profile of the drug remained consistent with prior studies, and the clinical data will be shared with global regulatory authorities, it said.